Proprietary Gene Delivery Technology
Total Trials
2
As Lead Sponsor
As Collaborator
0
Total Enrollment
185
NCT04313868
GEN2 Directed Cancer Immunotherapy Trial
Phase: Phase 1
Role: Lead Sponsor
Start: Jun 13, 2014
Completion: Dec 12, 2023
NCT06391918
Phase 1 Study of GEN2 in Patients With Advanced Solid Tumors
Start: Mar 4, 2024
Completion: Mar 1, 2028
Loading map...